Global Multiple Sclerosis Drugs Market Report Size, Trends & Growth Opportunity, By Type, By Distribution Channel, By Route of Administration, By Region and forecast till 2027
Report ID : QR1001430 | Industries : Chemicals & Materials | Published On :January 2022 | Page Count : 239Global Multiple Sclerosis Drugs Market
Multiple Sclerosis (MS), is the general neurological disorder which affects spinal cord and the brain. Multiple Sclerosis damages the myelin sheath which is a term which represents that material which surrounds and protects human nerve cells. This damage blocks the communication between different parts of the body and the brain and leads to the symptoms of Multiple Sclerosis including thinking and memory problems, visual disturbances, problem in synchronization and balancing of the body and muscle weakness.
Market Drivers
The government and non-governmental organizations are backing a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life. Thus, proactive government support and recommendations is likely to fuel the growth of the market.
Moreover, clinical studies for the treatment of multiple sclerosis are conducted by several pharmaceutical companies and Companies are working to create advanced medicines in multiple sclerosis radiology for patients suffering from the condition which is also helping to drive the growth of the market.
Know more about this report: request for sample pages
Market Restraints
The high cost of medications used to treat multiple sclerosis (MS) which restrain the growth of the market for multiple sclerosis drugs. MS is a disease which is not curable and with a high risk of impairment that necessitates lifetime therapy.
Market Segmentation
Multiple Sclerosis Drugs Market sis segmented into major 4 categories. Based on Type, the market is segmented into Immunosuppressants & Immunomodulators. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East.
Regional Analysis
North America reported for the largest share in the global Multiple Sclerosis Drugs Market in 2018, due to rise in demand for Multiple Sclerosis Drugs, easy availability of MS drugs and increase favourable reimbursement policies by government for MS treatment.
Europe is likely to be the second largest region in terms of revenue due to proactive government support, recommendations and reimbursement policies.
Market Key Players
Some of the key players operating in Global Multiple Sclerosis Drugs Market are Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd., among others.
Industry development
In August 2020, Genzyme Corporation agreed to buy Principia Biopharma Inc., a firm that develops therapy solutions for immune-mediated diseases. This acquisition added the company's research endeavors in the field of multiple sclerosis, as well as other immune-mediated diseases.
In July 2019, Copaxone (glatiramer acetate injection) is now available in the prefilled autoinjector YpsoMate from Teva Pharmaceuticals USA, Inc. This launch assisted patients in managing medicine doses and allowing them to give drug doses without the assistance of a drug administrator. This strategy improved the product portfolio and increased income.
Global Multiple Sclerosis Drugs Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Multiple Sclerosis Drugs Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Multiple Sclerosis Drugs Market, By Route of Administration
5.1 Y-o-Y Growth Comparison, By Route of Administration
5.2 Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
5.3 Multiple Sclerosis Drugs Market Size and Forecast, By Route of Administration
5.3.1 Oral
5.3.2 Injectable
6 Multiple Sclerosis Drugs Market, By Distribution Channel
6.1 Y-o-Y Growth Comparison, By Distribution Channel
6.2 Multiple Sclerosis Drugs Market Share Analysis, By Distribution Channel
6.3 Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
6.3.1 Hospital Pharmacies
6.3.2 Retail Pharmacies & Drug Stores
6.3.3 Online Pharmacies
7 Multiple Sclerosis Drugs Market, By Type
7.1 Y-o-Y Growth Comparison, By Type
7.2 Multiple Sclerosis Drugs Market Share Analysis, By Type
7.3 Multiple Sclerosis Drugs Market Size and Forecast, By Type
7.3.1 Immunosuppressants
7.3.2 Immunomodulators
8 Multiple Sclerosis Drugs Market, By Region
8.1 Multiple Sclerosis Drugs Market Share Analysis, By Region
8.2 Multiple Sclerosis Drugs Market Share Analysis, By Region
8.3 Multiple Sclerosis Drugs Market Size and Forecast, By Region
9 North America Multiple Sclerosis Drugs Market Analysis and Forecast (2021-2027)
9.1 Introduction
9.2 North America Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
9.3 North America Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
9.4 North America Multiple Sclerosis Drugs Market Size and Forecast, By Type
9.5 North America Multiple Sclerosis Drugs Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Multiple Sclerosis Drugs Market Analysis and Forecast (2021-2027)
10.1 Introduction
10.2 Europe Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
10.3 Europe Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
10.4 Europe Multiple Sclerosis Drugs Market Size and Forecast, By Type
10.5 Europe Multiple Sclerosis Drugs Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11 Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast (2021-2027)
11.1 Introduction
11.2 Asia Pacific Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
11.3 Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
11.4 Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, By Type
11.5 Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12 Latin America Multiple Sclerosis Drugs Market Analysis and Forecast (2021-2027)
12.1 Introduction
12.2 Latin America Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
12.3 Latin America Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
12.4 Latin America Multiple Sclerosis Drugs Market Size and Forecast, By Type
12.4 Latin America Multiple Sclerosis Drugs Market Size and Forecast, By Network Route of Administration
12.5 Latin America Multiple Sclerosis Drugs Market Size and Forecast, Country
12.5.1. Brazil
12.5.2. Rest of Latin America
13 Middle East Multiple Sclerosis Drugs Market Analysis and Forecast (2021-2027)
13.1 Introduction
13.2 Middle East Multiple Sclerosis Drugs Market Share Analysis, By Route of Administration
13.3 Middle East Multiple Sclerosis Drugs Market Size and Forecast, By Distribution Channel
13.4 Middle East Multiple Sclerosis Drugs Market Size and Forecast, By Type
13.5 Middle East Multiple Sclerosis Drugs Market Size and Forecast, By Country
13.5.1. Saudi Arabia
13.5.2. UAE
13.5.3. Egypt
13.5.4. Kuwait
13.5.5. South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Celgene Corporation
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Acorda Therapeutics, Inc.
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Biogen, Inc.
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Actelion Pharmaceuticals (Johnson & Johnson)
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 EMD Serono (Merck KGaA)
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Bayer AG
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Teva Pharmaceutical Industries Ltd.
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Novartis AG.
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Sanofi
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 F. Hoffmann-La Roche Ltd.
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies